KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $807000.0.

  • Travere Therapeutics' Gains from Investment Securities rose 14603.66% to $807000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 8028.01%. This contributed to the annual value of -$7.9 million for FY2024, which is 31908.44% down from last year.
  • Latest data reveals that Travere Therapeutics reported Gains from Investment Securities of $807000.0 as of Q3 2025, which was up 14603.66% from -$876000.0 recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Gains from Investment Securities ranged from a high of $13.9 million in Q3 2021 and a low of -$40.4 million during Q4 2021
  • Moreover, its 5-year median value for Gains from Investment Securities was $1.5 million (2021), whereas its average is $115736.8.
  • In the last 5 years, Travere Therapeutics' Gains from Investment Securities plummeted by 178966.81% in 2021 and then soared by 53104.4% in 2025.
  • Quarter analysis of 5 years shows Travere Therapeutics' Gains from Investment Securities stood at -$40.4 million in 2021, then surged by 109.97% to $4.0 million in 2022, then tumbled by 154.3% to -$2.2 million in 2023, then plummeted by 33.49% to -$2.9 million in 2024, then skyrocketed by 127.62% to $807000.0 in 2025.
  • Its last three reported values are $807000.0 in Q3 2025, -$876000.0 for Q2 2025, and $1.6 million during Q1 2025.